Sun Pharmaceutical Industries Ltd today said its US arm has resolved issues raised by the country’s health regulator regarding violation of manufacturing standards. “The US Food and Drug Administration (USFDA) has informed Sun Pharmaceutical Industries, Inc... that after a June, 2011, re-inspection of its Cranbury, New Jersey, US manufacturing facility, the site has an acceptable regulatory status,” Sun Pharma said in a statement. Therefore, the issues noted in the USFDA’s August 25, 2010, warning letter are considered to be resolved, it said.
